ClinicalTrials.gg
CompletedNCT04486924GPS-CAUpdated Feb 10, 2023

Performance and Safety of the Globe® Mapping and Ablation System With the GPS™ Module for the Treatment of Atrial Fibrillation

An interventional study of Globe Mapping and Ablation System in Atrial Fibrillation, sponsored by Kardium Inc.. Completed at 2 sites in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by Kardium Inc. · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.

Enrollment
242nd of 261
18 · median 282
Started
2021
with 14 others
No phase
135 of 318
28 open now
Registered
235th of 318
by date

Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 242nd largest by enrollment of the 261 interventional ones that give a count, is one of 15 that started in 2021, is one of 135 with no phase, and was the 235th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Atrial Fibrillation with a site in Canada, or all of them as a file.
02

Study summary

This study will evaluate the safety and acute performance of the Globe® Mapping and Ablation System with the GPS™ Module intended to conduct electroanatomic mapping and ablation treatment of subjects with atrial fibrillation (AF).

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years old and ≤75 years old
  2. Symptomatic AF with at least one AF episode electrocardiographically documented within one (1) year prior to enrolment. Documentation may include diagnosis in the patient medical files, (ECG), Trans-telephonic monitoring (TTM), Holter monitor or telemetry strip.
  3. Selected for catheter ablation for the treatment of atrial fibrillation

Exclusion criteria

Exclusion Criteria:

  1. History of previous left atrial ablation or surgical treatment for AF/AFL/AT
  2. for either catheter ablation or epicardial surgery (including, but not limited to: previous thoracic radiation, previous perimyocarditis, previous cardiac tamponade, pleural adhesions, and prior thoracotomy)
  3. Presence of LA thrombus by TEE, CT scan, MRI, or angiography
  4. Known conditions or anatomical abnormality that may interfere with the device delivery or positioning (e.g. myxoma, tumour, calcification, venous access path narrowing, or tortuosity)
  5. Planned concomitant cardiac surgery procedures besides AF treatment (valve, coronary, others)
  6. Uncontrolled heart failure or Class III or IV heart failure
  7. Valve repair or replacement or presence of a prosthetic valve
  8. Coronary artery bypass grafting, cardiac surgery, or valvular cardiac surgical procedure within the past 6 months
  9. MI or PCI procedure within 3 months before screening
  10. (LVEF) \< 40%
  11. Presence of implanted pacemaker or implantable cardioverter defibrillator (ICD)
  12. Severe pulmonary hypertension or prior pulmonary stenting
  13. History of cerebrovascular disease, including stroke or (TIA) within 6 months prior to enrollment
  14. Contraindication to anticoagulation (e.g., heparin)
  15. History of blood clotting or bleeding disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Globe Mapping and Ablation System

    Device: Globe Mapping and Ablation System

Interventions

  • DeviceGlobe Mapping and Ablation System

    Prospective, non-randomized, open-label clinical study.

06

What researchers measure

Primary outcomes

  1. Acute isolation of all clinically relevant pulmonary veins confirmed by entrance block

    Time frame: start to end of the procedure

  2. Procedure time

    Time frame: start to end of the procedure

  3. Catheter dwell time

    Time frame: start to end of the procedure

  4. Fluoroscopy time

    Time frame: start to end of the procedure

  5. Fluoroscopy dose area product

    Time frame: start to end of the procedure

  6. Incidence of Primary Adverse Events (PAE) occurring peri-procedurally and within 7 days (inclusive) of the ablation procedure

    Time frame: start to seven days after the end of the procedure

  7. Incidence of all serious adverse events occurring peri-procedurally and within 7 days (inclusive) of the ablation procedure

    Time frame: start to seven days after the end of the procedure

07

Study locations

2 sites
  • Southlake Regional Health Centre
    Newmarket, Canada
  • St. Paul's Hospital
    Vancouver, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2022, 16 months.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 16 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Jul 27, 2020
StartActual
Apr 5, 2021
Primary completionActual
Aug 30, 2022
CompletionActual
Aug 30, 2022
Last update
Feb 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04486924
Lead sponsor
Kardium Inc.
Responsible party
Sponsor
First posted
Jul 27, 2020
Start date
Apr 5, 2021
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Last update
Feb 10, 2023

Study contacts

Southlake Regional Health Centre
principal investigator · 596 Davis Dr, Newmarket ON L3Y 2P9, Canada

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion